Nigeria's federal government has recorded another step in its drive to strengthen local healthcare manufacturing with the signing of a Memorandum of Understanding aimed at producing micronutrient supplements for pregnant women within the country. The agreement was sealed between the Presidential Initiative for Unlocking the Healthcare Value Chain, known as PIVAC, and Remington Pharmaceutical Industries.
Under the agreement, the two parties are to commence the local production of multiple micronutrient supplements specifically intended for pregnant women. The initiative is presented as part of a wider push to build up Nigeria's capacity to manufacture essential health products on its own soil rather than relying on shipments from abroad.
Stakeholders involved in the deal say the move is expected to create jobs, enhance access to essential health products and reduce the country's dependence on imports. By situating the production line inside Nigeria, they argue, the supplements can be made more readily available to the women who need them while supporting local industry.
A central element of the partnership is the transfer of technology. According to those behind the project, the product in question has already been developed over the past three to four years, and that technology is now being brought into Nigeria as a first step towards localising production, so that there are no longer import dependencies for this particular product.
The partnership is also backed by key development partners, including UNICEF and the Gates Foundation, whose involvement stakeholders point to as a sign of growing confidence in Nigeria's healthcare manufacturing potential. The collaboration is framed as a way of improving access to essential health products across the wider region.
Those driving the initiative described Nigeria, as one of the largest countries in Africa, as pivotal to their plans for the continent. They added that a quality qualification from UNICEF serves as an assurance that the product meets the standard required to be distributed to pregnant women, a group they singled out as a key audience for the supplements.